Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22441388 | 1.00 | GRM4 (0.53) | GRM4TAS1R3TAS1R1LMNAHTT | |
| SCHEMBL29368182 | 1.00 | GRM4 (0.53) | GRM4TAS1R3TAS1R1LMNAHTT | |
| SCHEMBL22458106 | 0.84 | GRM4 (0.51) | GRM4LMNAHTTKDM4ESMN1; SMN2 | |
| SCHEMBL29368864 | 0.84 | TAS1R3 (0.61) | TAS1R3TAS1R1LMNACTSKSMN1; SMN2 | |
| SCHEMBL22441336 | 0.82 | TAS1R3 (0.54) | TAS1R3TAS1R1LMNACTSKMAPT | |
| SCHEMBL22441339 | 0.82 | TAS1R3 (0.54) | TAS1R3TAS1R1LMNACTSKMAPT | |
| SCHEMBL29368654 | 0.82 | TAS1R3 (0.54) | TAS1R3TAS1R1LMNACTSKMAPT | |
| SCHEMBL22441315 | 0.82 | TP53 (0.53) | TAS1R3TAS1R1KDM4ECTSKSMN1; SMN2 | |
| SCHEMBL22441316 | 0.82 | TP53 (0.53) | TAS1R3TAS1R1KDM4ECTSKSMN1; SMN2 | |
| SCHEMBL22441265 | 0.81 | CTSK (0.52) | TAS1R3TAS1R1KDM4ECTSKLPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3931183-B1 | COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE | FERRO THERAPEUTICS INC (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-114008024-A | Compounds having iron death inducing activity and methods of using the same | 费罗治疗公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20220002280-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2022-01-06 | — | — | US | disclosed |
| US-11040964-B2 | Compounds and methods of use | Ferro Therapeutics, Inc. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200299283-A1 | COMPOUNDS AND METHODS OF USE | BRIDGEBIO PHARMA, INC. | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002280-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | GRM4 1319/4885TAS1R3 3730/4885TAS1R1 3650/4885 |
| US-20200299283-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | GRM4 1319/4885TAS1R3 3730/4885TAS1R1 3650/4885 |
| US-11040964-B2 | Compounds and methods of use | AIFM2, GPX4, GPX1 | GRM4 1319/4885TAS1R3 3730/4885TAS1R1 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.